What are the current guidelines for migraine treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Current Guidelines for Migraine Treatment

The most current guidelines for migraine treatment recommend NSAIDs as first-line therapy for acute attacks, followed by triptans if NSAIDs fail, while preventive treatment should be considered for patients with frequent or disabling migraines, with CGRP antagonists like erenumab being strongly recommended for prevention. 1, 2

Acute Treatment

First-Line Treatment

  • NSAIDs are recommended as first-line treatment for most patients with migraine
    • Ibuprofen (400-600mg)
    • Naproxen sodium (500-550mg)
    • Aspirin (900-1000mg)
    • Acetaminophen-aspirin-caffeine combination 2

Second-Line Treatment

  • Triptans for patients whose migraine attacks do not respond to NSAIDs:
    • Eletriptan, frovatriptan, rizatriptan, sumatriptan (oral or subcutaneous), sumatriptan-naproxen combination, or zolmitriptan (oral or intranasal) 1
    • Dosing examples:
      • Sumatriptan: 50mg orally or 6mg subcutaneously for severe attacks
      • Rizatriptan: 10mg orally
      • Zolmitriptan: 2.5-5mg orally or intranasally 2

Newer Acute Treatments

  • CGRP receptor antagonists:
    • Rimegepant or ubrogepant are suggested for short-term treatment of migraine 1

Special Considerations

  • Use non-oral routes of administration when nausea/vomiting are significant
  • Add antiemetics for nausea
  • Limit use of acute medications to prevent medication overuse headache:
    • Triptans: no more than 9 days per month
    • NSAIDs: no more than 15 days per month 2

Preventive Treatment

Strong Recommendations

  • CGRP monoclonal antibodies:
    • Erenumab, fremanezumab, or galcanezumab are strongly recommended for prevention of episodic or chronic migraine 1, 3
    • Erenumab dosing: 70mg subcutaneously once monthly, with some patients benefiting from 140mg monthly 3

Moderate Recommendations

  • Intravenous eptinezumab is suggested for prevention of episodic or chronic migraine 1
  • Topiramate is suggested for prevention of episodic and chronic migraine 1
  • Beta blockers:
    • Propranolol (80-240 mg/day) is suggested for migraine prevention 1, 2
  • Other medications with weak recommendations:
    • Lisinopril for episodic migraine
    • Oral magnesium for migraine prevention
    • Valproate for episodic migraine
    • Memantine for episodic migraine
    • Atogepant for episodic migraine
    • OnabotulinumtoxinA for chronic migraine 1

Not Recommended

  • Against using:
    • Gabapentin for prevention of episodic migraine
    • AbobotulinumtoxinA or onabotulinumtoxinA for prevention of episodic migraine
    • Galcanezumab for prevention of chronic cluster headache 1

Indications for Preventive Treatment

  • ≥2 migraine attacks per month with disability for ≥3 days per month
  • Use of rescue medication more than twice a week
  • Failure of or contraindications to acute treatments
  • Presence of uncommon migraine conditions (e.g., hemiplegic migraine) 1, 2

Treatment Approach

  • Stratified care (selecting initial treatment based on headache severity) provides better outcomes than step care approaches 4
  • For mild to moderate attacks: Start with NSAIDs
  • For severe attacks or those not responding to NSAIDs: Use triptans
  • For refractory attacks: Consider combination therapy (NSAID + triptan) or rescue medications 5, 6

Special Populations

Pediatric and Adolescent Patients

  • Ibuprofen is recommended to treat pain in children/adolescents
  • In adolescents, consider sumatriptan/naproxen, zolmitriptan nasal, sumatriptan nasal, rizatriptan ODT, or almotriptan 1
  • Discuss evidence for amitriptyline combined with cognitive behavioral therapy, topiramate, and propranolol for prevention 1

Common Pitfalls to Avoid

  1. Medication overuse: Limiting acute medication use is crucial to prevent medication overuse headache
  2. Delayed treatment: Treating attacks early improves outcomes
  3. Inadequate dosing: Using subtherapeutic doses reduces effectiveness
  4. Ignoring contraindications: Triptans should not be used in patients with uncontrolled hypertension, cardiovascular disease, or basilar/hemiplegic migraine 2
  5. Overlooking non-pharmacological approaches: Regular sleep schedule, hydration, trigger avoidance, and stress management are important components of migraine management

By following these evidence-based guidelines and avoiding common pitfalls, clinicians can optimize migraine treatment outcomes and significantly improve patients' quality of life.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Migraine Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Acute Migraine Treatment.

Continuum (Minneapolis, Minn.), 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.